Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: A large-scale analysis of fresh frozen tissue samples

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Waldemarson, Sofia ^a   Kurbasic, Emila ^a   Krogh, Morten ^b   Cifani, Paolo ^a   Berggård, Tord ^c   Borg, Åke ^a   James, Peter ^a,d  

^a LUND UNIVERSITY   (Sweden)

^b Amber BioSciences AB   (Sweden)

^c Novo Nordisk Scandinavia   (Sweden)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Breast cancer; Mass spectrometry; Molecular subtyping; Proteomics; Transcriptomics

Indexed keywords

MESSENGER RNA; TRANSCRIPTOME;

ARTICLE; BREAST TUMOR; CLASSIFIER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HIERARCHAL CLUSTER; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; SELECTED REACTION MONITORING; SUPPORT VECTOR MACHINE; TANDEM MASS SPECTROMETRY; TRANSCRIPTOMICS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; BIOLOGY; BREAST NEOPLASMS; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; PROTEIN PROCESSING; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUPPORT VECTOR MACHINE; TANDEM MASS SPECTROMETRY; TRANSCRIPTOME;

EID: 84976494856     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0732-2     Document Type: Article

References (51)

1. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer. 1980;45(2):349-53.
2. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008;26(5):798-805.
3. Creighton CJ et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010;12(3):R40.
4. Perou CM et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
5. Sørlie T et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74.
6. Sorlie T et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-23.
7. Hu Z et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
8. Parker JS et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7.
9. Wang ZC et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004;64(1):64-71.
10. Jönsson G et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 2010;12(3):R42.
11. Troester MA et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004;64(12):4218-26.
12. Guiu S et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol. 2012;23(12):2997-3006.
13. Curtis C et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-52.
14. Jönsson G et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res. 2005;65(17):7612-21.
15. Nathanson KL, Weber BL. "Other" breast cancer susceptibility genes: searching for more holy grail. Hum Mol Genet. 2001;10(7):715-20.
16. Rafiq S et al. Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. Cancer Res. 2013;73(6):1883-91.
17. Jönsson G et al. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer. Cancer Res. 2012;72(16):4028-36.
18. Lakhani SR et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310-8.
19. Schwanhäusser B et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337-42.
20. Geiger T, Cox J, Mann M. Proteomic changes resulting from gene copy number variations in cancer cells. PLoS Genet. 2010;6(9):e1001090.
21. Myhre S et al. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol Oncol. 2013;7(3):704-18.
22. Omenn GS et al. Metrics for the Human Proteome Project 2015: Progress on the human proteome and guidelines for high-confidence protein identification. J Proteome Res. 2015;14(9):3452-60.
23. Waldemarson S et al. Large-scale proteomics analysis of human ovarian cancer for biomarkers. J Proteome Res. 2007;6(4):1440-50.
24. Mann M, Kelleher NL. Precision proteomics: the case for high resolution and high mass accuracy. Proc Natl Acad Sci USA. 2008;105(47):18132-8.
25. Olsson N et al. Grading breast cancer tissues using molecular portraits. Mol Cell Proteomics. 2013. doi: 10.1074/mcp.M113.030379.
26. Geiger T, Madden SF, Gallagher WM, Cox J, Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res. 2012;72(9):2428-39.
27. Waldemarson S et al. Protein expression changes in ovarian cancer during the transition from benign to malignant. J Proteome Res. 2012. doi: 10.1021/pr201258q.
28. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222.
29. Addona TA et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009;27(7):633-41.
30. Carr SA et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics. 2014;13(3):907-17.
31. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl. 2008;2(10-11):1386-402.
32. Hoofnagle AN et al. Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays. Clin Chem. 2016;62(1):48-69.
33. Ong S-E et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002;1(5):376-86.
34. Antberg L, Cifani P, Sandin M, Levander F, James P. Critical comparison of multidimensional separation methods for increasing protein expression coverage. J Proteome Res. 2012;11(5):2644-52.
35. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367-72.
36. Cox J et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011;10(4):1794-805.
37. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
38. Maclean B et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966-8.
39. Häkkinen J, Vincic G, Månsson O, Warell K, Levander F. The proteios software environment: an extensible multiuser platform for management and analysis of proteomics data. J Proteome Res. 2009;8(6):3037-43.
40. Nordenfelt P et al. Antibody orientation at bacterial surfaces is related to invasive infection. J Exp Med. 2012;209(13):2367-81.
41. Teleman J et al. Automated selected reaction monitoring software for accurate label-free protein quantification. J Proteome Res. 2012;11(7):3766-73.
42. Rios J, Puhalla S. PARP inhibitors in breast cancer: BRCA and beyond. Oncology (Williston Park, NY). 2011;25(11):1014-25.
43. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol. 2011;32(3):441-50.
44. Liu X-G et al. Ca2 + -binding protein S100A11: a novel diagnostic marker for breast carcinoma. Oncol Rep. 2010;23(5):1301-8.
45. Wilhelm M et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509(7502):582-7.
46. Liu NQ et al. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst. 2014;106(2):djt376.
47. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014;343(6178):1466-70.
48. Hedenfalk I et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA. 2003;100(5):2532-7.
49. Guedj M et al. A refined molecular taxonomy of breast cancer. Oncogene. 2012;31(9):1196-206.
50. Farmer P et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24(29):4660-71.
51. Herschkowitz JI et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76.